Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine for Mucosal Leishmaniasis
NCT01377974Phase 2Completed
- Sponsor
- Hospital Universitário de Brasília
- Start
- Jul 2009
- Primary completion
- Jun 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of miltefosine in mucosal leishmaniasis (ML) (2 arms), sponsored by Hospital Universitário de Brasília. Primary endpoint: Cure at 6 months. Started Jul 2009; status: completed.
02
Drugs
miltefosine
03
Conditions
mucosal leishmaniasis (ML)
Beyond the preview
Go deeper on NCT01377974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01377974.